The synthesis of mifepristone, an antiprogestin blocking the action of progesterone at the receptor level, started a new era of medical termination of pregnancy (MTOP). The initial results of MTOP with mifepristone alone were disappointing; however, mifepristone can sensitise the myometrium to the action of prostaglandins. Clinical trials have shown that the sequential administration of mifepristone followed 1–2 days later by a prostaglandin analogue is a safe, effective, and acceptable method for MTOP. This article will review the events and challenges leading to the development of the current evidence-based and yet off-label regimen for first-trimester MTOP. Tweetable abstract: This article reviews the events and challenges in the development of medical termination of pregnancy.
CITATION STYLE
Ho, P. C. (2017, December 1). Development of medical termination of pregnancy: a review. BJOG: An International Journal of Obstetrics and Gynaecology. Blackwell Publishing Ltd. https://doi.org/10.1111/1471-0528.14905
Mendeley helps you to discover research relevant for your work.